Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Robbins Umeda LLP Announces an Investigation of Immucor, Inc

VIEWS: 6 PAGES: 1

SAN DIEGO--(EON: Enhanced Online News)--Robbins Umeda LLP announces an investigation into Immucor, Inc. (NASDAQ: BLUD), following the board's decision to enter into acquisition proceedings with funds managed by TPG Capital img border='0' title='Add to Google' alt='Add to Google' s

More Info
									Robbins Umeda LLP Announces an Investigation
of Immucor, Inc.
July 05, 2011 08:07 PM Eastern Daylight Time 

SAN DIEGO--(EON: Enhanced Online News)--Robbins Umeda LLP, a shareholder rights litigation firm, is
interested in helping shareholders of Immucor, Inc. (NASDAQ: BLUD). The firm has commenced an investigation
into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of
Immucor in connection with their efforts to sell the company to funds managed by TPG Capital.

If you own stock in Immucor and would like more information about your shareholder rights, please contact Gregory
E. Del Gaizo at 800-350-6003 or via the shareholder information form on our website.

On July 5, 2011, Immucor announced it had entered into a definitive merger agreement under which TPG Capital
will acquire all outstanding shares of the company via an all cash tender offer. Under the terms of the agreement, no
later than July 15, 2011, IVD Acquisition Corporation, an affiliate of TPG Capital, is expected to commence a
tender offer to acquire all outstanding shares of Immucor for $27.00 per share. The transaction is expected to close
in the second half of 2011.

The investigation focuses on whether Immucor's board is undertaking a fair process to obtain maximum value and
adequately compensate its shareholders in light of the company's recent positive financial results. On April 6, 2011,
Immucor reported strong third-quarter earnings that greatly exceeded analyst expectations. The company reported a
diluted EPS of $0.32 and $83.30 million in revenue for the quarter. These results beat analyst estimates of an EPS of
$0.26 and revenue of $79.77 million for the same period. Taken together, Immucor's revenue figures for the quarter
represented a 4% increase from the prior year quarter.

Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action
lawsuits. Robbins Umeda LLP has helped its clients realize more than $1 billion of value for themselves and the
companies in which they have invested. The firm's skilled litigation teams include former federal prosecutors, former
defense counsel from top multinational corporate law firms, and career shareholder rights attorneys. For more
information, please go to http://www.robbinsumeda.com.

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/immucor-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts
Robbins Umeda LLP
Gregory E. Del Gaizo, 800-350-6003

								
To top